Splisense
Latest round
- Series B
Last raised
- May 2021
Total raised
- $29M
Investors
- 4
About Splisense
Splisense Ltd.Founded in 2016 and headquartered in Jerusalem, Israel, Splisense specializes in RNA-based therapies, focusing on ASOs to treat genetic pulmonary diseases.Splisense specializes in innovative RNA-based therapies utilizing Antisense Oligonucleotides (ASOs) to address pulmonary diseases. The company’s core offerings aim to restore and modify protein functionality by targeting specific genetic mutations that contribute to conditions such as cystic fibrosis, muco-obstructive pulmonary diseases, and idiopathic pulmonary fibrosis (IPF). The ASOs work by modulating gene expression and protein function, thereby providing therapeutic benefits for patients with these challenging conditions. Splisense’s technology is built upon the research of Professor Batsheva Kerem from the Hebrew University, highlighting the effectiveness of ASO-based treatments for genetic diseases.Splisense generates revenue through partnerships and collaborations with healthcare providers and research institutions, focusing on B2B transactions. Clients engage in contractual agreements that establish pricing structures based on the specific products offered, with potential pricing tiers reflecting the stages of development and clinical application of its therapies.5 mn on May 13, 2021, Splisense Ltd. plans to utilize these resources to advance its pipeline, specifically focusing on its lead ASO product, SPL84-23, which aims to treat the 3849+10kb C->T CFTR mutation. The company intends to initiate a Phase 1/2a trial in 2022. Furthermore, Splisense is strategizing to expand its market presence in North America and Europe, targeting an increase in partnerships with healthcare providers and research institutions, thus enhancing accessibility to its therapies.
Who invested in Splisense
4 investors across 1 round
See all investors in Splisense
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
May 13, 2021
Amount
$29M
Investors
Questions about Splisense
Who invested in Splisense?
Splisense has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Splisense raised?
Splisense has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Splisense last raise money?
Splisense's most recent round on record is a Series B, in May 2021.
What does Splisense do?
Splisense is a biotechnology company.
Where is Splisense headquartered?
Splisense is headquartered in Jerusalem, Israel.
Which VCs invest in companies like Splisense?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Splisense's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Splisense? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.